Scil Proteins and Cambridge Antibody Technology sign cross-license agreement for Affilin Technology and Ribosome Display
Cambridge Antibody Technology (CAT) and Scil proteins GmbH announced that they have signed a cross-licence agreement, under which both parties obtain substantial freedom to conduct research under certain of each others' intellectual property, as well as the right to develop a number of therapeutic, diagnostic and technical products. CAT obtains access to Scil Proteins' Affilin(TM) technology (Scil Proteins' proprietary scaffold technology), in the field of therapeutic indications and Scil Proteins gains rights to intellectual property in Ribosome Display controlled by CAT in the field of novel protein products.
Under the terms of the agreement, Scil Proteins obtains the right to use CAT's intellectual property in Ribosome Display to create and commercialise an unlimited number of Affilin(TM) derived recombinant proteins for therapeutic, diagnostic and technical applications. In addition Scil Proteins receives the right to sublicense the products to third parties.
CAT obtains not only the right to develop and commercialise therapeutic Affilin(TM) based products using Scil Proteins' proprietary scaffold technology, including the right to sublicense to collaboration partners, but can also use Scil Proteins' protein refolding know-how to enforce CAT's product developments.
Dr Ulrike Fiedler, Scil Proteins' Managing Director, commented, "The agreement underscores the enormous potential of alternative non-immunoglobulin derived binding proteins, such as our Affilin(TM) molecules for the development of novel targeted biotherapeutics. Scil Proteins' technology as well as CAT's business fields are being complemented and can be expanded in a perfect way. The attractive financial terms enable both parties to pursue their future businesses with great flexibility".
Other news from the department business & finance
